Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer
- Leveraging PLK1 based synthetic lethality to address RAS mutant metastatic colorectal cancer with a highly selective PLK-1 inhibitor, onvansertib
- Demonstrating potentially practice changing clinical activity and tolerability of onvansertib with FOLFIRI/bev in front line RAS-mut mCRC in a randomized controlled Phase II study
- Defining a clinical path toward approvability through ongoing first line development and combination with a standard chemotherapy backbone in an area of high unmet need with limited advancements